To view or add a comment, sign in Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology This article highlights a critical point for improving cardiovascular prevention strategies: Because clinicians will not treat what they do not measure, universal screening of hsCRP in both primary and secondary prevention patients, in combination with cholesterol, represents a major clinical opportunity and is therefore recommended
The net cardiovascular risk picture for most retatrutide patients is therefore: lower blood pressure, improved lipid profile, reduced systemic inflammation (lower hsCRP) alongside a modest heart rate elevation
Table of Contents Incidence and Mechanisms Behind Gallbladder Events Patient-Level Risk Factors and Weight-Loss Magnitude Monitoring Strategies and Clinical Thresholds Counseling Patients While Preserving Metabolic Benefits Incidence and Mechanisms Behind Gallbladder Events Reports of gallbladder-related adverse events during GLP-1 therapy have emerged across randomized trials and real-world analyses
No data support the efficacy of currently marketed patches
[DOI] [PMC free article] [PubMed] [Google Scholar] 69.Knop F.K., Aroda V.R., Vale R.D.D., Holst-Hansen T., Laursen P.N., Rosenstock J., Rubino D.M., Garvey W.T
Additionally, a 2024 commentary in Nature Reviews Endocrinology suggested that the future of GLP-1 use may be individualized dosing , guided by biomarker response and patient goals
